Panbela announces poster presentation at american association for cancer research: evaluating the potential of spermine analogue ivospemin (sbp-101) in combination with chemotherapy in ovarian cancer

Minneapolis, april 19, 2023 (globe newswire) -- panbela therapeutics, inc. (nasdaq: pbla), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs announces a poster presentation highlighting the results for ivospemin (sbp-101) as a polyamine metabolism modulator in ovarian cancer at the american association for cancer research (aacr), taking place april 14-19, 2023. the work reflects the company's ongoing collaboration with johns hopkins university school of medicine.
PBLA Ratings Summary
PBLA Quant Ranking